Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Phase 1
10
about 4.3 years
18+
1 site in CA
What this study is about
This trial is testing whether radiation therapy can help the immune system fight cancer. It uses imaging tests, like zirconium Zr 89-Df-crefmirlimab PET scans, to see if radiation therapy recruits CD8 T cells, which are important for fighting tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Intensity Modulated Radiation Therapy
- 2.Receive Stereotactic Body Radiation Therapy
- 3.Take Zirconium Zr 89-Df-Crefmirlimab
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: CD8 PET SUV (Subset), Evaluation of tumor response (fludeoxyglucose F-18 [FDG] PET and/or computed tomography [CT]) as it relates to both baseline CD8 PET SUV and changes observed after SBRT., Histology specific differences in immune characterization (CD8 PET SUV) and changes, Incidence of adverse events, Site specific differences in immune characterization (CD8 PET SUV) and changes, Time evolution of CD8 PET SUV (decay corrected)
radiation, imaging
Oncology